Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-OLE M54 – sTTR and KCCQ-OS
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-OLE M54-ACM, CVM, and NT-proBNP
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-sTTR Association with KCCQ
Presentation · Mar 2026 · PDF
BBIO-Acoramidis AG10-ACC 2026-Survey of Treatment Patterns and Preferences ATTR-CM
Publication · Mar 2026
Long-term durability of acoramidis efficacy: OLE of ATTRibute-CM
Publication · Feb 2026
Acoramidis in ATTR-CM: expanding evidence from ATTRibute-CM
Publication · Feb 2026
Impact of acoramidis on clinical stability: ATTRibute-CM (Bayer/BridgeBio)
Publication · Dec 2025